Stay updated with breaking news from Libtayo Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival                                                                                                                           Â...
FDA Approves Libtayo® as Monotherapy for Advanced NSCLC Search jobs Subject: FDA Approves Libtayo   Regeneron and Sanofi received U.S. FDA approval for Libtayo® (cemiplimab-rwlc, an PD-1 inhibitor) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%), %), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK or ROS1 ...
Sanofi: FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50% N=356 a 14 months Median (95% CI) b Based on stratified proportional hazards model An additional prespecified analysis was performed in 563 patients with proven PD-L1 expression of =50%, according to the FDA-approved assay, and is described in the updated labeling of the FDA-approved assay (and also recently published (https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-12-07-00-00) in The Lancet). This analysis showed that Li...
/PRNewswire/ -- Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics...